| Value | ₹4.09 Cr |
|---|
BSE filing, NSE: ACSTECH. Summary written from the filing by ALFA Finder's alert engine.
ACS Technologies Ltd: key numbers
- Share price
- ₹61.16
- Market cap
- ₹371.5 Cr
- Revenue (annual)
- ₹264.2 Cr
- Net profit (annual)
- ₹8.52 Cr
- P/E (TTM)
- 34.9×Sector 50.0×
- Promoter holding
- 37.37%-5.34% QoQ
- FII holding
- 0.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ACS Technologies Ltd
All →ACS Technologies Preferential Issue
ACS Technologies received trading approval for 49,50,495 preferential shares, trading from October 26, 2026. Issued at Rs.40.40 each, the allotment implies about Rs.200 Crore.
- Value
- ₹200.0 Cr
ACS Technologies Preferential Issue
ACS Technologies received listing approval for 49,50,495 equity shares issued on a preferential basis to non-promoters at ₹40.40 per share, totaling ₹20 Crore.
- Value
- ₹20.00 Cr
ACS Technologies Capital Structure Change
Non-promoter Adiniya Investments acquired 49.5 lakh ACS Technologies shares via loan-to-equity conversion on a preferential basis. This raised its stake to 7.13% of total share capital.
ACS Technologies Other Announcement
ACS Technologies Limited filed the quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended 30th September 2026.
ACS Technologies Annual General Meeting
ACS Technologies Limited conducted its 33rd Annual General Meeting on 30th September 2026, where the company discussed its financial performance and strategic growth initiatives.
ACS Technologies Capital Structure Change
ACS Technologies Limited received in-principle approval from BSE for the preferential issue of 49,50,495 equity shares. The shares are priced at Rs. 40.40 each to non-promoter entities.
- Value
- ₹20.00 Cr
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr